Skip to content

Prevention of early onset moderate to severe OHSS with GnRH antagonist after oocyte retrieval: a randomized controlled trial

Prevention of early onset moderate to severe OHSS with GnRH antagonist after oocyte retrieval: a randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043408
Enrollment
Unknown
Registered
2021-02-15
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian hyperstimulation syndrome

Interventions

group 1: GnRHantagonist
group 2:GnRHagonist
group 3:letrozole

Sponsors

Women and Children's Hospital Affiliated to Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Women aged 20-40 in the first assisted pregnancy cycle; 2) GnRH antagonist or long IVF / ICSI; 3) GnRHa or hCG trigger; 4) E2 >= 4680pg / ml and / or oocyte number >= 20 on hCG day; 5) All embryos were frozen.

Exclusion criteria

Exclusion criteria: 1) Severe heart, liver and kidney diseases; 2) Using coasting to prevent OHSS during ovulation induction; 3) Taking drugs that affect vascular permeability during art; Exclusion criteria: 1) Continued participation in clinical trials will cause unnecessary harm to the subjects; 2) The compliance of the subjects was poor, and they could not use the medicine on time and in quantity; 3) Use other drugs or foods that affect tolerance judgment or pharmacokinetic results; 4) At the same time, other treatments were used to evaluate the effect; 5) The subjects who did not meet the inclusion criteria were found after participating in the trial; 6) The subjects who met the exclusion criteria were found after participating in the trial; 7) The subjects who fell out; 8) In addition to the above situations, other subjects deviated from or violated the protocol during the trial and affected the drug equivalence evaluation or safety evaluation.

Design outcomes

Primary

MeasureTime frame
Incidence of early onset moderate to severe OHSS;Estradiol;progesterone;Hematocrit;C-reactive protein;

Countries

China

Contacts

Public ContactLin Jin

Women and Children's Hospital Affiliated to Xiamen University

fraulin@163.com+86 13600922041

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026